Evelo Biosciences

Evelo Biosciences Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Evelo Biosciences key operating metrics including Phase I Trials Products (Inflammation and Immunology), environmental, and social and governance score (ESG).

Phase I Trials Products (Inflammation and Immunology)

66.7%

FY, 2021

Product (Inflammation)

42.9%

FY, 2021

R&D Expenses (Oncology programs)

$84K

90.8%

Q1, 2022

Operating Metrics

Metrics	FY, 2019	FY, 2020	FY, 2021
Phase I Trials Products (Inflammation and Immunology)	2	3	1
Product (Inflammation)	5	7	4
R&D Expenses (Oncology programs)	$9.2M	$5.5M	$2.8M
R&D Expenses (Inflammation programs)	$25.2M	$30.5M	$37.4M
R&D Expenses (Platform)	$10.5M	$11.5M	$13.4M
Product (Oncology)	3	1	1
Phase II Trials Products (Inflammation and Immunology)		2	2

Environmental, Social and Governance (ESG)

Overall

40-49 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Learn more

Source:CSRHub

Footer menu

Product

Solutions

Resources

Company

Share price data provided by IEX